Newsletter Tool

Today’s Big News

Apr 1, 2024

No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis

Equillium’s lupus drug improves kidney biomarker, teeing up opt-in decision from Ono

ICYMI: What does it mean for a confirmatory trial to be 'well underway'? Regeneron wants to know

Could immunotherapy prevent breast cancer before it starts?

#FierceMadness: The Best Biotech Name Tournament—VOTE NOW

Featured

No reprieve for biopharma layoffs in Q1: Fierce Biotech analysis

By Gabrielle Masson

The biotech industry has been holding its breath, hoping that 2024 would bring some reprieve from 2023’s brutal bear market. But market recovery is a slow process, and the number of layoffs reported this quarter reflect that sentiment, with 57 layoff rounds reported for the first three months—the exact number reported during the same period last year.

Equillium’s lupus drug improves kidney biomarker, teeing up opt-in decision from Ono

By Max Bayer

Equillium’s add-on lupus treatment improved a biomarker of kidney function in an unblinded phase 1 study, setting the ball rolling toward Ono Pharmaceuticals’ court for future development work.

What does it mean for a confirmatory trial to be 'well underway'? Regeneron wants to know

By Annalee Armstrong

Days after Regeneron received a complete response letter for the blood cancer medicine odronextamab, hematology executive Andres Sirulnik says the trial is enrolling just fine—it’s just that randomization hasn’t begun.

Could immunotherapy prevent breast cancer before it starts?

By Helen Floersh

Researchers for the first time have identified dysfunctional immune cells in the healthy breast tissue of women with mutations in the genes BRCA1 and BRCA2, a finding that opens up the possibility of using existing immunotherapy drugs to prevent cancer before it forms.

#FierceMadness: The Best Biotech Name Tournament—VOTE NOW

By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron

What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket.

Eisai, Biogen's injectable Leqembi delayed as FDA asks for more data

By Angus Liu

What analysts viewed as a potential “inflection point” for Eisai and Biogen’s slow-footed Leqembi is facing a delay with the FDA.

'Unprecedented' demand for Eli Lilly's Zepbound sparks US supply constraints

By Zoey Becker

While the drug is not listed on the FDA's shortage list, some pharmacies are facing supply issues. Amazon Pharmacy, for instance, notes that several dosage strengths are "unavailable."

Abbott advances its hand-held, rapid blood test for TBI, concussions with new FDA clearance

By Conor Hale

You won’t see Abbott’s i-STAT Alinity test on the sidelines of sporting events just yet—but the FDA’s green light is a step in that direction, allowing the use of whole blood samples.

Teva snares up to $150M in Abingworth funding to propel late-stage asthma rescue inhaler

By Eric Sagonowsky

Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway for an asthma rescue inhaler.

Fierce podcasts

Don’t miss an episode

'The Top Line': The top money raisers in biotech

This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode.

SXSW Insights: The future of AI in healthcare

'The Top Line': A closer look at European biotech investment in 2024

Resources

Whitepaper

Oncology Market Outlook 2024

This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Guidance for Biotechs Choosing Next-Gen Contract GMP/CMC Labs

Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future.

PPD®️ Laboratory Services